Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C40H38F5N3O3S |
| Molecular Weight | 735.805 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C(SCC5=CC=CC(F)=C5F)=CC(=O)C6=C4C=CC=C6
InChI
InChIKey=NNBGCSGCRSCFEA-UHFFFAOYSA-N
InChI=1S/C40H38F5N3O3S/c1-51-22-21-46-19-17-32(18-20-46)47(24-27-9-11-28(12-10-27)29-13-15-31(16-14-29)40(43,44)45)37(50)25-48-35-8-3-2-6-33(35)36(49)23-38(48)52-26-30-5-4-7-34(41)39(30)42/h2-16,23,32H,17-22,24-26H2,1H3
| Molecular Formula | C40H38F5N3O3S |
| Molecular Weight | 735.805 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Rilapladib (SB659032) is a potent and selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Inhibition of Lp-PLA2 can reduce peripheral measures of inflammation. Rilapladib has been evaluated for treatment in Alzheimer’s disease and atherosclerosis. Initial results from clinical trials in Alzheimer patients suggests that oral administration of rilapladib may slow down the progression of Alzheimer’s disease. Initial evidence has also been found that inhibition of Lp-PLA2 may attenuate intimal macrophage accumulation and consequently stabilize atherosclerotic plaque.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study. | 2014-08 |
|
| Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study. | 2012 |
|
| Lipoprotein-associated phospholipase A(2) and atherosclerosis. | 2009-10 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:30:15 GMT 2025
by
admin
on
Mon Mar 31 18:30:15 GMT 2025
|
| Record UNII |
O14CWE893Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29703
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C76401
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY | |||
|
8704
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY | |||
|
O14CWE893Z
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY | |||
|
9918381
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY | |||
|
SUB64595
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104981
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY | |||
|
DB05119
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY | |||
|
412950-08-4
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY | |||
|
100000134795
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY | |||
|
DTXSID50194281
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY | |||
|
RR-58
Created by
admin on Mon Mar 31 18:30:15 GMT 2025 , Edited by admin on Mon Mar 31 18:30:15 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|